Skip to main content
Top
Published in: Diabetologia 3/2017

Open Access 01-03-2017 | Article

Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study

Authors: Louise J. C. J. den Biggelaar, Simone J. S. Sep, Simone J. P. M. Eussen, Andrea Mari, Ele Ferrannini, Marleen M. J. van Greevenbroek, Carla J. H. van der Kallen, Casper G. Schalkwijk, Coen D. A. Stehouwer, Pieter C. Dagnelie

Published in: Diabetologia | Issue 3/2017

Login to get access

Abstract

Aims/hypothesis

The hyperglycaemic clamp technique and the frequently sampled IVGTT are unsuitable techniques to assess beta cell function (BCF) in large cohorts. Therefore, the aim of this study was to evaluate the discriminatory ability of simple OGTT-based BCF indices for prediction of prediabetes (meaning impaired fasting glucose and/or impaired glucose tolerance) and type 2 diabetes.

Methods

Glucose metabolism status was assessed by 2 h 75 g OGTT at baseline (n = 476, mean age 59.2 years, 38.7% women) and after 7 years of follow-up (n = 416) in the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) study (1999–2009). Baseline plasma glucose, insulin and C-peptide values during OGTTs were used to calculate 21 simple indices of BCF. Disposition indices (BCF index × Matsuda index), to compensate for the prevailing level of insulin resistance, were calculated for the BCF indices with the best discriminatory abilities. The discriminatory ability of the BCF indices was estimated by the area under the receiver operating characteristics curve (ROC AUC) with an outcome of incident prediabetes (n = 73) or type 2 diabetes (n = 60 and n = 18 cases, respectively, in individuals who were non-diabetic or had normal glucose metabolism at baseline).

Results

For incident prediabetes (n = 73), all ROC AUCs were less than 70%, whereas for incident type 2 diabetes, I30/I0, CP30/CP0, ΔI30/ΔG30, ΔCP30/ΔG30 (where I, CP and G are the plasma concentrations of insulin, C-peptide and glucose, respectively, at the times indicated), and corrected insulin response at 30 min had ROC AUCs over 70%. In at-baseline non-diabetic individuals, disposition indices ΔI30/ΔG30, ΔCP30/ΔG30 and corrected insulin response at 30 min had ROC AUCs of over 80% for incident type 2 diabetes. Moreover, these BCF disposition indices had significantly better discriminatory abilities for incident type 2 diabetes than the Matsuda index alone.

Conclusions/interpretation

BCF indices reflecting early-phase insulin secretion have the best ability to discriminate individuals who will develop prediabetes and type 2 diabetes. Of these, ΔCP30/ΔG30, often referred to as the C-peptidogenic index, performed consistently well.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bergman RN, Finegood DT, Kahn SE (2002) The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Investig 32(Suppl 3):35–45CrossRef Bergman RN, Finegood DT, Kahn SE (2002) The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Investig 32(Suppl 3):35–45CrossRef
2.
go back to reference Cobelli C, Toffolo GM, Dalla Man C et al (2007) Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293:E1–E15CrossRefPubMed Cobelli C, Toffolo GM, Dalla Man C et al (2007) Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests. Am J Physiol Endocrinol Metab 293:E1–E15CrossRefPubMed
3.
go back to reference Pacini G, Mari A (2003) Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17:305–322CrossRefPubMed Pacini G, Mari A (2003) Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 17:305–322CrossRefPubMed
4.
go back to reference Ahren B, Pratley RE, Soubt M, Dunning BE, Foley JE (2008) Clinical measures of islet function: usefulness to characterize defects in diabetes. Curr Diabetes Rev 4:129–145CrossRefPubMed Ahren B, Pratley RE, Soubt M, Dunning BE, Foley JE (2008) Clinical measures of islet function: usefulness to characterize defects in diabetes. Curr Diabetes Rev 4:129–145CrossRefPubMed
5.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419CrossRefPubMed
6.
go back to reference Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL (2014) Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 10:2–42CrossRefPubMedPubMedCentral Cersosimo E, Solis-Herrera C, Trautmann ME, Malloy J, Triplitt CL (2014) Assessment of pancreatic beta-cell function: review of methods and clinical applications. Curr Diabetes Rev 10:2–42CrossRefPubMedPubMedCentral
7.
go back to reference Kruijshoop M, Feskens EJM, Blaak EE, de Bruin TWA (2004) Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 341:33–40CrossRefPubMed Kruijshoop M, Feskens EJM, Blaak EE, de Bruin TWA (2004) Validation of capillary glucose measurements to detect glucose intolerance or type 2 diabetes mellitus in the general population. Clin Chim Acta 341:33–40CrossRefPubMed
8.
go back to reference van Greevenbroek MM, Jacobs M, van der Kallen CJ et al (2011) The cross‐sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Investig 41:372–379CrossRef van Greevenbroek MM, Jacobs M, van der Kallen CJ et al (2011) The cross‐sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Investig 41:372–379CrossRef
9.
go back to reference World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF Consultation. WHO, Geneva World Health Organization (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF Consultation. WHO, Geneva
10.
go back to reference Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed Kahn SE, Prigeon RL, McCulloch DK et al (1993) Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663–1672CrossRefPubMed
11.
go back to reference Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470CrossRefPubMed
12.
go back to reference Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E (2002) Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 283:E1159–E1166CrossRefPubMed
13.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
14.
go back to reference Brouwers MC, Cantor RM, Kono N et al (2006) Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res 47:2799–2807CrossRefPubMed Brouwers MC, Cantor RM, Kono N et al (2006) Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res 47:2799–2807CrossRefPubMed
15.
go back to reference Jacobs M, van Greevenbroek MM, van der Kallen CJ et al (2011) The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metab Clin Exp 60:969–975CrossRefPubMed Jacobs M, van Greevenbroek MM, van der Kallen CJ et al (2011) The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study). Metab Clin Exp 60:969–975CrossRefPubMed
16.
go back to reference Jacobs M, van Greevenbroek MM, van der Kallen CJ et al (2011) The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Investig 41:167–175CrossRef Jacobs M, van Greevenbroek MM, van der Kallen CJ et al (2011) The association between the metabolic syndrome and peripheral, but not coronary, artery disease is partly mediated by endothelial dysfunction: the CODAM study. Eur J Clin Investig 41:167–175CrossRef
17.
go back to reference Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D (2003) Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 56:1163–1169CrossRefPubMed Wendel-Vos GC, Schuit AJ, Saris WH, Kromhout D (2003) Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol 56:1163–1169CrossRefPubMed
18.
go back to reference DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics 44:837–845 DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristics curves: a nonparametric approach. Biometrics 44:837–845
20.
go back to reference Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198CrossRefPubMed Hanson RL, Pratley RE, Bogardus C et al (2000) Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 151:190–198CrossRefPubMed
21.
go back to reference Lorenzo C, Hazuda HP, Haffner SM (2012) Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab 97:793–799CrossRefPubMed Lorenzo C, Hazuda HP, Haffner SM (2012) Insulin resistance and excess risk of diabetes in Mexican-Americans: the San Antonio Heart Study. J Clin Endocrinol Metab 97:793–799CrossRefPubMed
22.
go back to reference Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638–1644CrossRefPubMed Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57:1638–1644CrossRefPubMed
23.
24.
go back to reference Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548CrossRefPubMed Abdul-Ghani MA, Williams K, DeFronzo RA, Stern M (2007) What is the best predictor of future type 2 diabetes? Diabetes Care 30:1544–1548CrossRefPubMed
25.
go back to reference Ram J, Snehalatha C, Selvam S et al (2015) The oral disposition index is a strong predictor of incident diabetes in Asian Indian prediabetic men. Acta Diabetol 52:733–741CrossRefPubMed Ram J, Snehalatha C, Selvam S et al (2015) The oral disposition index is a strong predictor of incident diabetes in Asian Indian prediabetic men. Acta Diabetol 52:733–741CrossRefPubMed
26.
go back to reference Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907 Retnakaran R, Shen S, Hanley AJ, Vuksan V, Hamilton JK, Zinman B (2008) Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test. Obesity 16:1901–1907
27.
go back to reference Solomon TP, Malin SK, Karstoft K et al (2014) Determining pancreatic beta-cell compensation for changing insulin sensitivity using an oral glucose tolerance test. Am J Physiol Endocrinol Metab 307:E822–E829CrossRefPubMedPubMedCentral Solomon TP, Malin SK, Karstoft K et al (2014) Determining pancreatic beta-cell compensation for changing insulin sensitivity using an oral glucose tolerance test. Am J Physiol Endocrinol Metab 307:E822–E829CrossRefPubMedPubMedCentral
28.
go back to reference Utzschneider KM, Prigeon RL, Faulenbach MV et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341CrossRefPubMedPubMedCentral Utzschneider KM, Prigeon RL, Faulenbach MV et al (2009) Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 32:335–341CrossRefPubMedPubMedCentral
29.
30.
go back to reference Ferrannini E, Mari A (2004) Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47:943–956CrossRefPubMed Ferrannini E, Mari A (2004) Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 47:943–956CrossRefPubMed
31.
go back to reference Mari A, Pacini G, Brazzale AR, Ahren B (2005) Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 48:748–751CrossRefPubMed Mari A, Pacini G, Brazzale AR, Ahren B (2005) Comparative evaluation of simple insulin sensitivity methods based on the oral glucose tolerance test. Diabetologia 48:748–751CrossRefPubMed
32.
go back to reference Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192CrossRefPubMed Levy JC, Matthews DR, Hermans MP (1998) Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:2191–2192CrossRefPubMed
34.
go back to reference Perley M, Kipnis DM (1966) Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 15:867–874CrossRefPubMed Perley M, Kipnis DM (1966) Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 15:867–874CrossRefPubMed
35.
go back to reference Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292 Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286–292
36.
go back to reference Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH (1988) The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500–1506CrossRefPubMed Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH (1988) The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500–1506CrossRefPubMed
37.
go back to reference Wareham N, Byrne C, Hales C, Phillips D (1995) The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12:931CrossRefPubMed Wareham N, Byrne C, Hales C, Phillips D (1995) The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12:931CrossRefPubMed
38.
go back to reference Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H (1976) Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading. Diabetes 25:241–244CrossRefPubMed Sluiter WJ, Erkelens DW, Reitsma WD, Doorenbos H (1976) Glucose tolerance and insulin release, a mathematical approach I. Assay of the beta-cell response after oral glucose loading. Diabetes 25:241–244CrossRefPubMed
39.
go back to reference Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301CrossRefPubMed Stumvoll M, Mitrakou A, Pimenta W et al (2000) Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 23:295–301CrossRefPubMed
40.
go back to reference Hansen T, Drivsholm T, Urhammer SA et al (2007) The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 30:257–262CrossRefPubMed Hansen T, Drivsholm T, Urhammer SA et al (2007) The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance. Diabetes Care 30:257–262CrossRefPubMed
Metadata
Title
Discriminatory ability of simple OGTT-based beta cell function indices for prediction of prediabetes and type 2 diabetes: the CODAM study
Authors
Louise J. C. J. den Biggelaar
Simone J. S. Sep
Simone J. P. M. Eussen
Andrea Mari
Ele Ferrannini
Marleen M. J. van Greevenbroek
Carla J. H. van der Kallen
Casper G. Schalkwijk
Coen D. A. Stehouwer
Pieter C. Dagnelie
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-4165-3

Other articles of this Issue 3/2017

Diabetologia 3/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine